

Nyrada Inc.

Investor Presentation
August 2024

Improving Lives, Offering Hope

Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board.

ASX:NYR

Important Notice and Disclaimer

This presentation has been prepared by Nyrada Inc **("NYR"** or **"Company"**). It should not be considered as an offer or invitation to subscribe for, or purchase any securities in NYR, or as an inducement to purchase any securities in NYR. No agreement to subscribe for securities in NYR will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice, and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Nyrada’s Expertise in Drug Development

- Drug discovery and development company specialising in novel small molecule therapeutics.
- Nyrada’s lead drug candidate, NYR-BI03:
  - demonstrated strong (preclinical) efficacy protecting the brain from secondary injury.
  - currently undergoing Good Laboratory Practice safety and tolerability testing.
  - preclinical TBI efficacy study with Walter Reed Army Institute of Research and UNSW currently in progress.
- Commercially focused business model and expert team.

Nyrada Investment Proposition

- Brain injury program - significant target market and unmet clinical demand.
- First-in-class neuroprotection therapy with novel mode of action.
- Pioneering transient receptor potential canonical (TRPC) channel blocking therapies.
- Collaborations with world leading institutions, Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney.
- Proven and globally experienced board and team.
- Cash position of A$4.77M at 30 June 2024.
- Expected R&D rebate around December 2024.

Brain Injury Trajectory, Patient Outcomes, Treatment Aims

Serial reconstruction from MRI







Nyrada drug NYR-BI03
An acute 3-day intravenous treatment

Reduce secondary injury resulting from stroke or TBI
- **Improve survivability, limit disability**
- **Improve quality of life**

TRPC 3/6/7 Ion Channels as a Therapeutic Target

- **Glutamate release** following brain injury **results in calcium entry** via TRPC ion channels
- **Excessive calcium** build-up leads to **neuronal cell death**
- **Blocking TRPC 3/6/7 ion channels is neuroprotective** against secondary brain injury



Near Term Catalysts

NYR-BI03:

- 2HCY2024 – Good Laboratory Practice (GLP) safety and tolerability study updates.
- 3QCY2024 – Walter Reed (WRAIR) traumatic brain injury/UNSW pre-clinical efficacy study update.
- 4QCY2024 – Human Research Ethics Committee application submission.
- 4QCY2024 – First-in-human Phase I clinical trial.

Brain Injury Program - Indicative Phase I Study Design

OBJECTIVES To assess the safety, tolerability, and pharmacokinetics of NYR-BI03

DESIGN

- Randomised, double-blind placebo – controlled, dose escalation design
- 5 cohorts; 8 participants each cohort; 6:2 active and placebo treatments
- 3 cohorts will be single ascending doses
- 2 cohorts will be given continuous infusion doses

PARTICIPANTS

- Male and female healthy volunteers
- 18 – 50 years age

Cohort number	Dose administered
1	Low dose single bolus
2	Medium dose single bolus
3	High dose
4	Low dose continuous infusion (72 hrs)
5	High dose continuous infusion (72 hrs)

LOCATION & DURATION

- Study will be conducted at a clinical trial centre in Australia 2H CY2024
- The study duration will vary between 1 – 4 days



*trial design subject to ethics approval

Contact Nyrada

Contact Nyrada Inc:

- Email: info@nyrada.com
- Web: www.nyrada.com
- Subscribe: www.nyrada.com/site/contact/email-alerts
- Phone: +61 2 9498 3390

Brain Injury Solution Animation

Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board.